Sunshine Biopharma, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $8.1 million, a decrease of 9.1% from $8.9 million in the same period last year. The decline in sales is attributed primarily to the termination of distribution agreements effective December 31, 2025. The company's cost of sales for the quarter was $5.9 million, resulting in a gross profit of $2.2 million, which represents a gross margin of 27%, down from 30.7% in the prior year. The net loss for the quarter was $1.2 million, or $0.25 per share, compared to a net loss of $1.2 million, or $0.44 per share, in the first quarter of 2025.
In terms of operational changes, Sunshine Biopharma's general and administrative expenses decreased to $3.6 million from $4.0 million year-over-year. This reduction was driven by lower consulting and marketing expenses, although there were increases in legal fees and salaries. The company also reported interest income of $48,426, down from $75,367 in the previous year, reflecting a decrease in cash reserves. Additionally, Sunshine Biopharma received a one-time payment of $103,320 related to a settlement with its former auditor, which contributed to the overall financial results.
The company continues to focus on its strategic initiatives, including the development of proprietary drugs such as K1.1 mRNA for liver cancer and SBFM-PL4, a protease inhibitor targeting SARS Coronavirus infections. Sunshine Biopharma operates through its subsidiaries, Nora Pharma and Sunshine Biopharma Canada, which collectively offer 60 generic prescription drugs in Canada. The company has plans to launch 12 additional drugs in 2026, aiming to strengthen its position in the Canadian generic drug market, valued at approximately $11.2 billion.
As of March 31, 2026, Sunshine Biopharma reported cash and cash equivalents of $6.9 million, down from $9.1 million at the end of 2025. The company used $2.1 million in operating activities during the quarter, an increase from $1.7 million in the same period last year. Sunshine Biopharma anticipates that its existing cash reserves, combined with revenue from sales, will be sufficient to fund operations for the next 17 months. However, the company acknowledges the need for additional capital in the future to support its expansion and research initiatives.
Looking ahead, Sunshine Biopharma aims to increase sales and streamline operations to achieve breakeven and reduce reliance on capital markets. The company is actively pursuing opportunities to enhance its product offerings and market presence, particularly in the Canadian pharmaceutical landscape. The management remains focused on navigating the challenges posed by market conditions and regulatory environments while advancing its proprietary drug development programs.
About Sunshine Biopharma, Inc
Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing generic, OTC, and proprietary medicines across therapeutic areas such as oncology and antivirals. It owns a portfolio of approved generics in Canada, develops novel drug candidates including mRNA-based cancer therapies and coronavirus inhibitors, and seeks to expand its market presence through licensing, licensing agreements, and strategic partnerships. The company emphasizes innovation, regulatory compliance, and competitive positioning in global markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.